Fidelity Investments’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Fidelity Investments’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,935	Closed	-$46.6K	–	5684
2023 Q1	$46.6K	Buy	1,935 +982	+103%	+$12.3K	﹤0.01%	3477
2022 Q4	$10.1K	Sell	953 -49,222	-98%	-$397K	﹤0.01%	4012
2022 Q3	$226K	Buy	50,175 +49,548	+7,902%	+$226K	﹤0.01%	3018
2022 Q2	$3K	Sell	627 -206	-25%	-$977	﹤0.01%	4516
2022 Q1	$6K	Buy	+833	New	+$4.98K	﹤0.01%	4410

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments's PRVB Position: Q2 2023 in Review

Fidelity Investments sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 1,935 shares — an estimated $46.6K sold.

Fidelity Investments first reported a position in PRVB in Q1 2022 and held it in 5 quarters. The position peaked at $226K in Q3 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Fidelity Investments reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Fidelity Investments sold 1,935 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $46.6K.
Fidelity Investments first reported a position in Provention Bio, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Fidelity Investments's Provention Bio, Inc. Common Stock position peaked at $226K in Q3 2022.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.